HMGB1 and cervical cancer: However, HMGB1 secretion during cervical cancer progression impairs the antiviral response by inhibiting IFNα secretion and increasing ICOSL (Inducible T Cell Costimulator Ligand) expression by plasmacytoid dendritic cells (pDCs).